CLINICAL TRIALS PROFILE FOR L-CITRULLINE
✉ Email this page to a colleague
Clinical Trials for L-Citrulline
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00280683 ↗ | Effects of L-arginine Supplementation in Adults With Moderate to Severe Asthma | Completed | National Center for Research Resources (NCRR) | Phase 2 | Nitric oxide is an important marker of airway inflammation in asthma. Nitric oxide may have a protective role in patients with moderate to severe asthma. The investigators believe that a natural amino acid, L-arginine, that augments nitric oxide levels can decrease asthma exacerbations and improve the asthma care of moderate to severe asthma patients. This study is a randomized, placebo controlled trial in which subjects will receive either 3 months of L-arginine supplementation or a placebo. The investigators will monitor subjects' symptoms, the number of asthma exacerbations, and lung function. In addition, we will draw blood, obtain induced sputum samples and measure exhaled breath nitric oxide levels at each monthly visit. |
NCT00280683 ↗ | Effects of L-arginine Supplementation in Adults With Moderate to Severe Asthma | Completed | National Institutes of Health (NIH) | Phase 2 | Nitric oxide is an important marker of airway inflammation in asthma. Nitric oxide may have a protective role in patients with moderate to severe asthma. The investigators believe that a natural amino acid, L-arginine, that augments nitric oxide levels can decrease asthma exacerbations and improve the asthma care of moderate to severe asthma patients. This study is a randomized, placebo controlled trial in which subjects will receive either 3 months of L-arginine supplementation or a placebo. The investigators will monitor subjects' symptoms, the number of asthma exacerbations, and lung function. In addition, we will draw blood, obtain induced sputum samples and measure exhaled breath nitric oxide levels at each monthly visit. |
NCT00280683 ↗ | Effects of L-arginine Supplementation in Adults With Moderate to Severe Asthma | Completed | University of California, Davis | Phase 2 | Nitric oxide is an important marker of airway inflammation in asthma. Nitric oxide may have a protective role in patients with moderate to severe asthma. The investigators believe that a natural amino acid, L-arginine, that augments nitric oxide levels can decrease asthma exacerbations and improve the asthma care of moderate to severe asthma patients. This study is a randomized, placebo controlled trial in which subjects will receive either 3 months of L-arginine supplementation or a placebo. The investigators will monitor subjects' symptoms, the number of asthma exacerbations, and lung function. In addition, we will draw blood, obtain induced sputum samples and measure exhaled breath nitric oxide levels at each monthly visit. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for L-Citrulline
Condition Name
Clinical Trial Locations for L-Citrulline
Trials by Country
Clinical Trial Progress for L-Citrulline
Clinical Trial Phase
Clinical Trial Sponsors for L-Citrulline
Sponsor Name